Sanofi – a world leader in diabetes drug development – is exiting diabetes research. The announcement on 9 December, one day ahead of the French company's capital markets day presentation, is not surprising given the commercial challenges Sanofi has faced in the therapy area in recent years, but it's not insignificant either.
Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research
The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.
